Genzyme Corporation (GENZ) and Isis Pharmaceuticals, Inc. (ISIS) announced the filing of the application for Marketing authorization for Mipomersen (Kynamro (R))

Free newsletters
Archive
My eNewsletters

News by subject
News by disease
News by date
PLoS
Search News
Publish your news
JoVE

Job seeker Login
Latest work
Research works
Post Resume
Career fairs
Career resources
For employers

Login
Become a Member
Discussion Forum
Frequently asked questions

Regional news
USA & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
NC Biography
BioForest
Southern Pharm
BioCanada East
US device
Europe
Asia


Market summary
News
IPO

Company profiles

Companies
Events

Store search

Biotech Events
Publish an event
Real Estate
Business opportunities

7/28/2011 08:22:25

CAMBRIDGE, Mass. & CARLSBAD, Calif. – (BUSINESS WIRE)--Genzyme, a company Sanofi (EURONEXT: SAN and NYSE: SNY) and Isis Pharmaceuticals Inc. (NASDAQ: ISIS) announced today that Genzyme has submitted a marketing authorization application (MAA) to the European Medicines Agency seeking approval for a weekly dose of 200 mg of mipomersen for treatment of severe homozygous and heterozygous familial hypercholesterolemia.

View the original article here